Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03679650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Aug 31, 2026 to Dec 31, 2026 Interventions: DC/AML fusion cells (Biological) to DC/AML fusion cells (Biological) · Eligibility criteria expanded, about 44 words Show 2 more changesShow less
    • Interventions: DC/AML fusion cells (Biological) to DC/AML fusion cells (Biological)
    • Eligibility criteria expanded, about 44 words
  2. Re-verified, no change to tracked fieldsv11
  3. Primary completion date: Aug 31, 2025 to Mar 31, 2026 Primary endpoint revised · Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 45 to confirmed 28 · 3 morev10 Show 6 more changesShow less
    • Primary endpoint revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 45 to confirmed 28
    • Interventions: DC/AML fusion cells (Biological), decitabine (Drug) to DC/AML fusion cells (Biological)
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site details revised at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Aug 31, 2024 to Aug 31, 2025v9
  5. Primary completion date: Aug 31, 2023 to Aug 31, 2024v8
Show 6 earlier versionsHide 6 earlier versions
  1. Lead sponsor: Dana-Farber Cancer Institute to Beth Israel Deaconess Medical Center Collaborators: 1 to 2v7 Show 1 more changeShow less
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv6
  3. Primary completion date: Aug 31, 2021 to Aug 31, 2023 Completion date: Aug 31, 2024 to Aug 31, 2026v5 Show 1 more changeShow less
    • Completion date: Aug 31, 2024 to Aug 31, 2026
  4. Re-verified, no change to tracked fieldsv4
  5. Site details revised at 1 of 2 sitesv3
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 24, 2018 to Oct 11, 2018 · Site details revised at 2 of 2 sites · Study title shortened, about 12 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Sep 24, 2018 to Oct 11, 2018
    • Site details revised at 2 of 2 sites
    • Study title shortened, about 12 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) * Decitabine, a chemotherapy drug
Trial Details
NCT Number NCT03679650
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: National Cancer Institute (NCI), Dana-Farber Cancer Institute
Conditions Acute Myelogenous Leukemia
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov